- Home
- POM vs CSTL Comparison
POM vs CSTL Comparison
Compare POM & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POM
- CSTL
- Stock Information
- Founded
- POM 2015
- CSTL 2007
- Country
- POM China
- CSTL United States
- Employees
- POM N/A
- CSTL N/A
- Industry
- POM Other Specialty Stores
- CSTL Medical Specialities
- Sector
- POM Consumer Discretionary
- CSTL Health Care
- Exchange
- POM Nasdaq
- CSTL Nasdaq
- Market Cap
- POM 640.8M
- CSTL 661.7M
- IPO Year
- POM 2025
- CSTL 2019
- Fundamental
- Price
- POM $5.82
- CSTL $31.06
- Analyst Decision
- POM
- CSTL Strong Buy
- Analyst Count
- POM 0
- CSTL 6
- Target Price
- POM N/A
- CSTL $37.67
- AVG Volume (30 Days)
- POM 3.2M
- CSTL 287.3K
- Earning Date
- POM 01-01-0001
- CSTL 11-03-2025
- Dividend Yield
- POM N/A
- CSTL N/A
- EPS Growth
- POM N/A
- CSTL N/A
- EPS
- POM N/A
- CSTL N/A
- Revenue
- POM $46,931,528.00
- CSTL $346,269,000.00
- Revenue This Year
- POM N/A
- CSTL N/A
- Revenue Next Year
- POM N/A
- CSTL N/A
- P/E Ratio
- POM N/A
- CSTL N/A
- Revenue Growth
- POM 12.37
- CSTL 20.40
- 52 Week Low
- POM $3.47
- CSTL $14.59
- 52 Week High
- POM $5.67
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- POM N/A
- CSTL 82.03
- Support Level
- POM N/A
- CSTL $23.31
- Resistance Level
- POM N/A
- CSTL $24.64
- Average True Range (ATR)
- POM 0.00
- CSTL 1.30
- MACD
- POM 0.00
- CSTL 0.58
- Stochastic Oscillator
- POM 0.00
- CSTL 95.21
About POM POMDOCTOR LIMITED American Depositary Shares
Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of revenue is derived from the Pharmaceutical supply chain segment.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.